Stockreport

PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial

PDS Biotechnology Corporation  (PDSB) 
Last pds biotechnology corporation earnings: 11/7 06:00 am Check Earnings Report
PDF 60% of evaluable patients demonstrated a clinical response             Clinical activity observed at all dose levels Data support previously reported i [Read more]